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resumo 
 
 
Este relatório descreve as atividades que desenvolvi no âmbito do meu estágio 
curricular na Blueclinical, Lda., na área de negócio “Clinical Research 
Partnership”. O estágio teve a duração de 10 meses, durante o qual 
desempenhei funções de coordenação de investigação clínica em dois 
hospitais diferentes: no Centro Hospitalar de Vila Nova de Gaia / Espinho entre 
Julho de 2013 e Fevereiro de 2014, e no Hospital Garcia de Orta a partir de 
Março de 2014. 
Este estágio insere-se no âmbito do Mestrado em Biomedicina Farmacêutica, 
da Universidade de Aveiro, e constitui o meu primeiro contacto com o mundo 
profissional. 
Neste relatório é revisto o estado da arte da investigação clínica em Portugal e 
no Mundo. Posteriormente encontram-se descritas as principais atividades 
desempenhadas no estágio, que se relacionam com a coordenação de ensaios 
clínicos e alguns estudos observacionais, e também com a gestão e 
implementação de gabinetes de investigação clínica nos hospitais. 
Este estágio foi uma ótima oportunidade a nível profissional, uma vez me 
permitiu terminar a minha formação académica já com uma experiência prática 
sólida. 
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abstract 
 
This report describes the activities developed during my internship at 
Blueclinical, Ltd, in the business unit “Clinical Research Partnership”. The 
internship lasted for 10 months, in which I performed clinical research 
coordination activities at two different hospitals: at “Centro Hospitalar de Vila 
Nova de Gaia / Espinho” between July 2013 and February 2014, and at 
“Hospital Garcia de Orta” since March 2014. 
This internship is within the scope of the Master’s degree in Pharmaceutical 
Medicine, in the University of Aveiro, and it is my first contact with the 
professional world. 
This report reviews the current state-of-the-art of clinical research, both in 
Portugal and Worldwide. Afterwards, there are described the main activities 
performed in this internship, which are related to the coordination of clinical 
trials and some observational studies, and also with the management and 
implementation of clinical research offices in the hospitals. 
The internship was a great professional opportunity, as it allowed me to finish 
my academic background already with a solid practical experience. 
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1. INTRODUCTION 
This report covers my curricular internship in Blueclinical, Ltd, which is integrated within the 
scope of the Master’s Degree in Pharmaceutical Medicine, at the University of Aveiro. The 
company is composed by three main business areas. One of them is Blueclinical CRP, standing for 
“Clinical Research Partnership”. CRP is based in the creation of partnerships with Portuguese 
health institutions, promoting their growth, efficiency and excellence in clinical research with drugs 
and medical devices”(1). I developed the internship in this business area, working as a Clinical 
Research Coordinator (CRC) for 10 months. From July 2013 to February 2014 I worked in “Centro 
Hospitalar de Vila Nova de Gaia / Espinho”, and since March 2014 in “Hospital Garcia de Orta”, 
in Almada.  
1.1. CURRICULAR INTERNSHIP OBJECTIVES 
Before the internship I had only a conceptual idea about what it was to be a clinical research 
coordinator and about the scope of activity of Blueclinical. Posting that, the main objective I 
defined for the internship was to learn about the role of a CRC and understand clinical research 
coordination. As secondary objectives, I aimed to develop my communication skills as well as my 
sense of responsibility, time management, autonomy and problem-solving ability. 
Only after a few time acquainting with the company and job role I have been provided with, by the 
company, I could define a new set of more specific goals: 
 To understand all the phases of a clinical trial from the site’s point of view, since the 
moment the site is contacted for feasibility, throughout the trial conduction itself, until 
close-out visit and archiving; 
 To comprehend the practical application of the International Conference of Harmonisation  
Good Clinical Practices (ICH-GCP) and regulatory requirements; 
 To establish a contact network with the hospital staff and Clinical Research Associates 
(CRAs)  to promote easier communication; 
 To have a good professional relationship will all co-workers both from Blueclinical and the 
hospital. 
 
2 
 
1.2. HOST INSTITUTION AND PARTNER HOSPITALS 
1.2.1. BLUECLINICAL, LTD. 
“Blueclinical – Investigação e desenvolvimento em saúde, Lda”, throughout this report referred to 
as Blueclinical, is a Portuguese company headquartered in the city of Porto. It is composed by three 
core business units, covering different sequential phases of clinical research and all the value chain 
in clinical development: the R&D (Research and Development) unit provides consultancy to help 
basic researchers translating their discoveries into applied research, supporting the initial 
development; the Phase I unit supports the earlier development in human volunteers; the CRP 
(Clinical Research Partnership) supports research in confirmatory phases in Portuguese institutions. 
Thus, Blueclinical covers all processes, “from bench to bedside”, turning out possible to get 
discoveries made in laboratory available to patients in real-life conditions. Besides these main 
areas, the company gets support from other departments, namely quality assurance, business 
development, medical writing and data management and statistics (1). 
The company was founded only two-years ago, and it has two partners: “Bluepharma, SA” and 
Professor Luís Almeida. From Bluepharma, the company inherited the “blue”, both the prefix and 
the colour of the company’s logo. Below there is a description of each business area, with further 
detail in CRP as it was the unit of my internship. 
BLUECLINICAL R&D 
The R&D unit serves the purpose of translation between basic and applied research. There were 
many companies investing in “bench” research lately, mostly small sized, and whose results have 
translation potential. This means that new drugs are being discovered that lack the know-how for 
developing their molecules into drug products(2). Blueclinical R&D provides consultancy to these 
companies, some of them start-ups, in the development of their projects with the ultimate goal of 
commercialization(3). 
Consultancy activities of Blueclinical R&D comprise the creation of pharmaceutical, pre-clinical, 
clinical, and regulatory development plans, preparation and follow-up of scientific advice, creation 
of the investigator brochure (IB) and experimental drug dossier, and helping the business 
development process and selection of portfolio(3). 
Consultancy is provided for both medicinal products and medical devices. 
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BLUECLINICAL PHASE I 
Blueclinical Phase I is a dedicated unit to phase I clinical trials, operating in a ward of Hospital da 
Prelada, Porto. The facilities are modern and renewed, providing all the necessary comfort and 
safety to conduct this type of research. 
Blueclinical Phase I mission is to conduct phase I studies in healthy volunteers (at Hospital da 
Prelada) and early-proof-of-concept studies in selected patient populations (at other hospitals, 
specifically contracted as a clinical research site for such type of studies). Among those studies in 
healthy volunteers, the following are included: i) bioavailability/bioequivalence studies, to 
determine whether different formulations of the same drug are equivalent; ii) food-interaction 
studies, to determine whether a drug should be taken with or without food; iii) drug-drug 
interactions studies, to determine whether a drug affects or is affected by simultaneous use of other 
medication; iv) tolerability and pharmacokinetic studies, to know the potential adverse effects and 
how the human body handles and eliminates a drug. 
To be able to perform these studies, the phase I unit is constantly requiring healthy volunteers. To 
apply to volunteer, a candidate must complete the form available in the website of Blueclinical, 
where all general information is also available (4).  
As there are very few early-phase trials in Portugal, this unit can largely contribute to change this 
situation, thus bringing high-value to the country.  
CLINICAL RESEARCH PARTNERSHIP 
Previously named Blueclinical SMO (meaning Site Management Organization), this business area 
is the one where I developed my internship. It is based in the creation of partnerships with 
Portuguese institutions, with the aim of improving their activity in clinical research. Blueclinical 
CRP’s mission is “to support the activity of clinical research partners, promoting their growth, 
efficiency and excellence in clinical research with drugs and medical devices”(1, p3). The CRP 
network counts with several entities, as shown in Figure 1. Blueclinical is not considered a 
Contract Research Organisation (CRO) as it is not a service provider. Instead, Blueclinical 
establishes win-win partnership relationships with affiliated Institutions with the main goal to 
accommodate all stakeholders’ interests, namely: patients, investigators, institutions, sponsors, 
society and collaborators. 
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Figure 1 Entities associated to the CRP network 
In each hospital of the network the partnership is concretized in an agreement of collaboration, 
leading to the creation of a structure dedicated to support clinical research activities, and whose 
name varies according to the institution’s organogram. This structure aims to coordinate, support 
and develop clinical trials in the institution, strictly adhering to ICH-GCP, applicable laws and 
other ethical principles. In “Centro Hospitalar de Vila Nova de Gaia / Espinho” (CHVNG/E), the 
clinical research office was structured as represented in Figure 2, and similar structures are found in 
the remaining hospitals. The Clinical Research Office, (in Portuguese “Gabinete de Investigação 
Clínica” - GIC), is composed by a coordinator, a supporting office (“Gabinete de Apoio ao 
Gabinete de Investigação Clínica” - GAGIC), and all clinical investigators that desire to become 
associated with the office (5). The coordinator is a physician named by the hospital’s 
Administration Board (AB), who will facilitate the integration of the office within the institution. 
GAGIC is formed by collaborators from Blueclinical CRP: a local Clinical Research Manager, 
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where applicable, and one or more CRCs that will perform the operational work of the office. Each 
Blueclinical collaborator must sign a confidentiality agreement with the institution, because there 
will be access to patient information, which is strictly confidential data. Associate Clinical 
Investigators are all physicians from the institution who wish to become associated with GIC and 
that undergo a training programme in clinical research, ICH-GCP and quality management. This 
training is named “Clinical Investigator Certification” (CLIC), and it is provided for free by 
Blueclinical. The office reports to the Clinical Operations Director of Blueclinical, which in turn 
reports to the management of the company. In “Hospital Garcia de Orta” (HGO), this office is 
named “Centro de Investigação Clínica” (CIC). 
 
 
Figure 2 Structure of clinical research office of CHVNG/E. 
The functions of supporting offices (e.g. GAGIC) are to deal with clinical trials submission 
processes, and then to support clinical teams in every administrative and logistical aspect related to 
the clinical trial (e.g. identifying patients, organising clinical visits, introducing data in CRFs (Case 
Report Forms), organising the Investigator Site Files (ISF), and also to keep tracking of the 
payments coming from research). They are also responsible for preparing eventual audits and 
inspections and implement Corrective Actions and Preventive Actions (CAPA) (5).These concepts 
will be discussed in the next sections. 
Blueclinical CRP is also composed by a back-office that helps with the administrative duties of 
each office. Blueclinical supports clinical investigators in studies of their own initiative, by 
providing templates of essential documents, performing regulatory submissions, and then support 
the preparation of statistics and publication of results. 
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The two pillars of CRP are quality and training: one objective for Blueclinical CRP is to have a 
quality management system (SQIC – “Sistema de Qualidade em Investigação Clínica”), defining in 
Standard Operating Procedures (SOPs) and procedures the critical activities of clinical trials, thus 
ensuring that ICH-GCP and all applicable ethical and legal requirements are fulfilled. In 
collaboration with each partner institution, CRP will draft a quality manual for clinical research 
that must be reviewed and approved by the institution’s AB. SOPs will be drafted and 
implemented, covering critical activities performed by each clinical research office. After SQIC is 
properly defined and implemented, healthcare professionals will be trained and those who are 
interested may become associated with the office. 
 
1.2.2. CENTRO HOSPITALAR DE VILA NOVA DE GAIA/ESPINHO 
“Centro Hospitalar de Vila Nova de Gaia/Espinho” was the first hospital in which I developed my 
internship. It is an institution that serves a big area of influence (covering about700.000 
inhabitants), reason why it has a great potential for investment in clinical research (6). The hospital 
has three units, each one functioning in a different building. The unit I of the hospital operates in 
the old facilities of a sanatorium constructed in the beginning of the XX century, when tuberculosis 
became a big threat for Portuguese people. Some years later, health priorities changed and the 
sanatorium was converted to a central hospital – “Hospital Eduardo Santos Silva”. CHVNG/E was 
the trail-blazer for pneumology and pulmonary surgery in Portugal, and it still keeps this 
therapeutic orientation. Later on, there was a redesign of the national health system that created 
“Centro Hospitalar de Vila Nova de Gaia/Espinho” by joining together this facility with two 
others: “Hospital Distrital de Gaia”, which is now the unit II of CHVNG/E, and “Hospital Nossa 
Senhora da Ajuda de Espinho”, which is unit III(6). These three units are shown in Figure 3. 
Currently, most of the medical specialties are located in unit I, including the emergency room. I 
spent most of the time of my internship in unit I, as it was the location of our Clinical Research 
Office. 
Unit II serves the departments of orthopaedics, maternal and child specialities (departments of 
gynaecology/obstetrics, paediatrics, neonatology and paediatric surgery), and the assisted 
reproduction centre, pre-natal diagnosis and a supportive operatory room. 
Unit III has the ambulatory surgery department and the unit of palliative care.  
CHVNG/E is an institution with potential to perform more and better clinical research. It is focused 
on the training of health professionals and on providing specialized, high-quality healthcare. 
Promoting innovation and playing a role in the development of new solutions for disease is 
mentioned in the hospital’s vision(6). Besides, the AB recognizes how important clinical research 
 7 
 
is as a strategy to improve the general training and the treatment options provided to patients(5). 
The greatest attractiveness factor is still the large amount of patients served by this institution, 
leading to a large pool from where possible patients can be recruited for clinical trials. 
 
   
Figure 3 The three units of CHVNG/E: unit I on the left, unit II in the middle, unit III on the right.(6) 
1.2.3. HOSPITAL GARCIA DE ORTA 
“Hospital Garcia de Orta, E.P.E.” (Figure 4) was created in 1991 due to a population increase in 
the area, which the existent hospitals could no longer address. It is located nearby Lisbon, and it 
was the first institution in the southern margin of Tagus River to be classified as a central hospital, 
in 2003. This hospital serves a population of 350 thousand inhabitants in the areas of Almada, 
Sesimbra and Seixal, plus all the Setubal peninsula in neonatology and neurosurgery. Through the 
years there were new services being created, such as renal transplant and the intervention 
cardiology unit. 
The hospital’s vision is to become the reference hospital in the Setubal peninsula and in all 
southern Portugal for some therapeutic areas. The hospital’s mission is to provide specialised 
healthcare to the population, and to develop training and research activities. 
HGO is accredited by CHKS (Caspe Healthcare Knowledge Systems) in pathologic anatomy, 
operatory room, sterilisation, logistic management, imuno -haemotherapy, and clinical pathology. 
 
Figure 4 “Hospital Garcia de Orta, E.P.E.” (7) 
This hospital is known by the quality of training of healthcare professionals, and considers clinical 
research as highly important in their development strategy.  
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1.3. REPORT STRUCTURE 
This report is structured in five chapters. The first is this one, defining the general scope of the 
internship, preliminary training objectives and the description of the host institution. The second 
chapter describes the current state-of-the-art of clinical research, contextualising the reader in the 
field by describing what is clinical research and which types of studies are considered, and it also 
describes the ethical and regulatory context, what new paradigms of research are emerging, an 
provides an overview of distribution in the world and in Portugal. In chapter three are described all 
the activities I developed during the internship regarding clinical trials and also activities related to 
the hospitals’ integration with Blueclinical and on-the-job training. Chapter four is the discussion 
and provides a more personal review of the internship, regarding objectives accomplished, 
differences between the two hospitals and the main difficulties I felt. Chapter five is my 
conclusion. 
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2. CLINICAL RESEARCH STATE OF THE ART 
Clinical research is basically defined by the National Institutes of Health (8) as any research 
involving living human subjects. It is concretised in the conduction of clinical trials (interventional 
research with medicines or medical devices) and observational studies (non-interventional studies, 
evaluating normal clinical practice). The ICH-GCP, one of the most important documents in this 
area, define a clinical trial or study as “any investigation in human subjects intended to discover or 
verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational 
product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study 
absorption, distribution, metabolism, and excretion of an investigational product(s) with the object 
of ascertaining its safety and/or efficacy”(9, p3). 
Clinical research may address the study of mechanisms of disease, new therapies, interventions or 
technologies for disease, epidemiological studies and also studies of behaviour and outcomes (8). 
Clinical research is the critical part of clinical development, which is the whole process since a new 
molecule is discovered until it turns into a new medicinal product or medical device getting 
marketing approval. The purpose of development is to discover if the new drug can be safe and 
effective in a specific dose range and schedule, and to establish a benefit-risk relationship that must 
be acceptable in order for the drug to be approved (10). The first step is the discovery of a new 
molecule with therapeutic potential from basic research. That molecule is called the “lead” and 
must then be developed in order to enter pre-clinical evaluation. After being studied in in vitro and 
in animal models, clinical development requires a determined set of clinical trials, which can be 
categorised in four different phases. Traditionally, these were sequentially named phase I, II, III 
and IV. A molecule must only step through one phase to another by proving its benefit in each 
phase. Nowadays, the terms “Human pharmacology studies”, “Therapeutic exploratory studies”, 
“Therapeutic confirmatory studies”, and “Therapeutic use studies” are considered more accurate. In 
general terms, they would be a match, although this change happened because phases don’t 
necessary have to be sequential, as explained in Figure 5 (11). 
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Figure 5 Correlation between development phases and types of study (11) 
The objectives and examples of each type of study is the following: 
 Human pharmacology studies (Phase I): These are performed in healthy volunteers or in 
selected populations of patients. These studies are the most controlled, and those in which 
inclusion criteria are stricter, because there is usually very limited information available on 
the molecule (12). They include first-in-men studies, designed to assess tolerance and 
identify the maximum tolerated dose, to determine Pharmacokinetic (PK) and 
Pharmacodynamic (PD) profiles in humans, to explore metabolism and drug interactions, 
and to estimate activity (11). 
 Therapeutic exploratory studies (Phase II): The most important exploratory studies are 
those concerning Proof of concept”. As the name states, the purpose of these studies is to 
prove that the drug does what it is supposed to. They are performed in small populations of 
target patients (12). Objectives include exploring the use in the targeted indication, 
estimate dosage and provide support for confirmatory studies (11). 
 Therapeutic confirmatory studies (Phase III): Confirmatory studies aim to confirm the 
effectiveness of the drug when used in more similar conditions to daily practice. A large 
number of patients is included, as these studies will provide the benefit/risk relationship to 
support regulatory approval, and so they must be close to the “reality” (12). Their purpose 
is to confirm efficacy, establish safety profiles and dose-response relationships (11). 
 Therapeutic Use (Phase IV): These are conducted when the drug is already on the market. 
“Post approval” studies aim to gather additional information about the drug usage in real-
life conditions. Because they reach to a large number of patients, they allow identification 
of less common adverse reactions, and thus a redefinition of benefit/risk relationship and 
dosing recommendations (11). They may also study pharmacoeconomy, or pursue a safety 
purpose by addressing pharmacovigilance (12). 
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Besides clinical trials, which consist in interventional research, there are also observational studies. 
This type of research is non-interventional, meaning that the study does not interfere with normal 
clinical practices and conditions. Observational studies can be categorized in four types (13):  
 Ecological- The “unit” studied is the group instead of the individual (e.g. relation of fat 
intake to risk of cancer, per country). 
 Cross-sectional - A study that describes a specific time point, as in a snapshot. The 
exposure and the outcome are measured simultaneously. They are mostly used to study 
prevalence (14). 
 Case-control - Two groups are chosen: one group of patients and other group of people 
without the disease. Then predictor variables are evaluated, such as exposure to risk 
factors. 
 Cohort- Subjects are followed up over a time frame. The cohort starts with a sample of 
exposed and not exposed individuals, and over the course of time it evaluates the 
development of an outcome (e.g., disease progression)(14). They can be prospective, when 
exposure to risk factor and outcome both occur after the study initiation; or retrospective, 
when both exposure and outcome occurred prior to the study. 
 
Clinical research and the overall drug development process can be highly demanding and complex. 
In order to achieve success, every one of the stakeholders must be engaged in the process (Figure 
6). 
The sponsor is normally the pharmaceutical company, but can also be an individual or an 
institution, which takes the responsibility for initiating, managing and/or financing a clinical trial 
(9). The clinical trial site is the location where the trial is conducted: it is usually a Hospital but can 
also be laboratory or other facilities. A CRO is an organisation contracted by the sponsor to 
perform one or more of the sponsor’s functions and duties in a clinical trial (9). They can be 
delegated all development activities or just a part. The research team is the group of people that 
contribute to the conduction of the trial in a site: the responsible physician is the Principal 
Investigator (PI), which leads the rest of the team. The other physicians are named sub-
investigators or co-investigators. Team is also constituted by nurses, pharmacists and maybe 
administrative or laboratory personnel (15). Regulatory Authorities are bodies with the power to 
regulate and inspect. In Portugal, the regulatory authority is INFARMED (“Autoridade Nacional 
do Medicamento e Produtos de Saúde, IP”), which authorizes the conduction of the trial, CEIC 
(“Comissão de Ética para a Investigação Clínica”), which must give a favourable opinion, and 
CNPD (“Comissão Nacional de Proteção de Dados”), which authorizes the disclosure of the data 
involved in a clinical trial. Subjects are all individuals which provide inform consent and 
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participate in a clinical trial. They may be patients or healthy volunteers. Hospital ABs are also a 
stakeholder because they must review a financial contract for each trial to be conduct in their 
facilities and provide approval. 
 
 
Figure 6 The main stakeholders in a clinical trial (15) - adapted. 
From the site’s point of view, a clinical trial is constituted by sequential phases of implementation 
and conduction. The first step occurs when a new trial proposal arrives to the site. That is called a 
feasibility assessment: when the sponsor has a new clinical trial designed and plans to implement it 
in various research centres, they perform a feasibility study in order to select which centres will 
perform the trial. It consists in a questionnaire that is sent to the sites to collect information about 
the staff availability, facilities and logistics, administrative constrains, and more specifically about 
the medical experience in the therapeutic area, number of patients treated at the site and how many 
patients would the site be able to recruit. The answers are then returned to the sponsor. After the 
sponsor receives several feasibility questionnaires, they will perform a pre-selection of sites, based 
on the answers given by each one, and then contact those of their choice. Then, a qualification visit 
(or Site Selection Visit – SSV) is arranged between the sponsor and the site, in which a 
representative of the sponsor that comes to the hospital and meets with the PI and its team, and 
checks the conditions of the site (ex. pharmacy, equipment, experience, motivation, etc.). By the 
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ICH-GCP, an investigator must be “qualified by training and experience” to perform a clinical trial, 
and it must have adequate resources available (9). 
If the site is selected, the negotiation of the financial contract and submission process can occur. At 
first, the sponsor submits the study to INFARMED, CEIC and CNPD, and then it submits to the 
hospital’s AB and local ethics committee when applicable. 
After approval or even during the process, the sponsor organises investigator meetings. The 
purpose of these meetings is to present the investigational plan to the teams and explain specific 
details in order to promote the trial’s success. There can be also investigator meetings later on, 
when the trial is already happening. 
After all approvals are collected, trial initiation can begin. A site initiation visit (SIV) is scheduled, 
in which the CRA trains the team in the trial procedures, and responsibilities are delegated through 
team members. When everything is set up, it is time to recruit patients and make all the effort of 
submission worth it. Enrolling patients is the ultimate goal for everyone involved in a trial. Patients 
will provide the data for the study to be conclusive, which will lead to the sponsor paying to the 
site, thus motivating the team. Besides, as working for a company which is external to the hospitals 
and surviving out of clinical trial payments, enrolling patients is the key to success. 
After a patient is included, there are sequential patient visits with procedures that vary according to 
the protocol. Although, some of them are common: the patient must always sign the informed 
consent form (ICF) before entering the trial; there are always IVRS (Interactive Voice Response 
Systems) or IWRS (Interactive Web Response Systems) systems to allocate medication, blood and 
urine samples to manage and send, among other tasks I will further describe in section 3. 
In the end, when all patients complete or discontinue the study, and when the sponsor considers, 
there will be a close-out visit where the dossiers are closed and can no longer be changed. The 
management of these activities on daily basis is focused on section 3. 
 
2.1. APPLICABLE ETHICAL AND REGULATORY CONTEXT 
Presently, there are various laws and regulations applicable to clinical research. In its core, clinical 
research equals human experimentation: if used in its best potential it can bring huge benefits in 
health, science and knowledge, if used improperly it can lead to people being treated like guinea 
pigs in the most outrageous ethical conditions (16). The first flagrant example were the Nuremberg 
trials, when Nazi doctors coerced the prisoners in concentration camps into their hazardous 
experiments without any type of consent. Following this, the Nuremberg code was created in 1947, 
being the first code for protecting human subject in clinical trials. Based on the same facts, the 
Declaration of Helsinki was created and adopted in 1964, protecting the subject’s rights in clinical 
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trials and stating that the interests of the subject must always prevail over the interests of science 
(17). Since the original version, it was updated several times, being the most recent version from 
October 2013. 
As ethical concerns in clinical research were addressed, regulatory systems in different countries 
became to reflect them as mandatory principles. In Europe, regulatory harmonisation of the clinical 
trials and approval systems remotes to the creation of the common market with the treaty of Rome. 
In the European Union (EU), laws assume the form of directives, regulations, guidelines, and other 
opinion papers and recommendations. These documents differ in scope and applicability: 
regulations overrule national laws and have immediate application in the community countries; 
directives must be transposed to the national law of each country; guidelines are published by 
scientific committees with no legally binding value, although they are an official reference. In 
medicines regulation, directives are adopted by the 27 Member States plus 3 countries from the 
European Economic Area: Iceland, Lichtenstein and Norway (18). All regulations and guidelines 
applicable to pharmaceuticals are collected in 10 volumes of “The Rules governing medicinal 
products in the European Union”, also known as Eudralex (18). 
Following the success harmonisation in the EU, regulatory authorities from Europe, the United 
States of America and Japan wished to expand harmonisation trough these three regions. In 1990, it 
was created the ICH – “International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use”. The ICH developed tripartite guidelines covering 
the main focus topics for developing new drugs: efficacy, safety and quality. This harmonisation 
resulted in a great benefit: as the regulatory requirements are the same, industry needed to perform 
less testing; as drug application forms are similar, regulatory assessment became easier; and 
industry could shift its focus into innovation instead of spending resources in bureaucracy. Drug 
development was fastened, whilst safeguarding the issues about safety, quality and efficacy (19). 
One of the guidelines provided by the ICH, the E6 or “Guideline for Good Clinical Practice” (ICH-
GCP) (9) is considered an international quality standard when it comes to clinical trials involving 
human subjects. It stands the principles for design, conduct, record and report of trials. Compliance 
with ICH-GCP assures that the rights, safety and well-being of the subjects are protected, and 
clinical trial data are quality and credible. These principles are consistent with the ones in the 
Declaration of Helsinki, and thus will ease the acceptance of data to support regulatory approval in 
the ICH regions.  
ICH-GCP defines as pillars that a trial must be scientifically sound, described in a detailed 
protocol, and should only begin after a foreseeable risk/benefit relationship is defined based on the 
available information from pre-clinical and other clinical trials. The rights and safety of the subject 
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also prevail over other interests, and each subject must give informed consent before entering the 
trial. All information is confidential, respecting the subject’s privacy. The trial must be conducted 
according to the protocol, and information must be dealt with in a way that allows accurate 
reporting, interpretation and verification (9). 
The responsible authority for evaluating medicines it the EU is the EMA (European Medicines 
Agency). In was created in 1995, with the aim to ensure the protection and promotion of public and 
animal health (20). It uses resources from all the Member-States and coordinates them for the 
evaluation, supervision and pharmacovigilance of pharmacovigilance of medicinal products (18). 
Regarding current regulatory practice in the EU, “Directive 2001/20/EC of the European 
Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and 
administrative provisions of the Member States relating to the implementation of good clinical 
practice in the conduct of clinical trials on medicinal products for human use" is the most important 
and it is known as “The clinical trials directive”. It states the requirements for conducting clinical 
trials in the EU, and outside if the drug intents to be marketed in the EU (21). All the ongoing or 
completed trials within the scope of this directive are contained in EudraCT, a large European 
database that provides the authorities with the necessary information to communicate and oversee 
clinical trials and drug development (21). 
This directive was further concretised in the "Commission Directive 2005/28/EC of 8 April 2005 
laying down principles and detailed guidelines for good clinical practice as regards investigational 
medicinal products for human use, as well as the requirements for authorisation of the 
manufacturing or importation of such products", known as the ICH-GCP Directive (22).  
In Portugal, 2001/20/EC was transposed into decree-law 46/2004, of August 19th. In April 16, 
2014, a new clinical research law was published – Law 21/2014 – replacing law 46/2004 and 
incorporating dispositions for trials with medical devices (23). 
Despite being a regulatory pillar for medicines development in Europe, Directive 2001/20/EC was 
much criticised, as it somehow hindered the clinical research activity instead of promoting it. To 
increase European competitiveness in the field, a new European regulation was proposed on July 
17, 2012: "Proposal for a Regulation of the European Parliament and of the Council on clinical 
trials on medicinal products for human use, and repealing Directive 2001/20/EC” (24). This will 
replace directive 2001/20/EC, and by assuming the form of a regulation its application will be 
equal throughout the European countries (thereby reducing differences in transposition for local 
languages which led to divergences with 2001/20/EC). The proposal redefines the concept of 
clinical trial and clinical study, simplifies the approval submission when the risk from the IMP 
(Investigational Medicinal Product) is considered low, states new authorisation procedures, new 
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ways of reporting safety information, and introduces an EU Portal through which trial data and 
information will be introduced and store in the EU database. The proposal for regulation is 
expected to be in practice in 2016 (24).  
2.2. CLINICAL RESEARCH WORLDWIDE 
The locations with more tradition in clinical trials are North America, Western Europe and 
Oceania. Regarding the number of trial sites (centres where the research is performed), the United 
States of America lead with eight times more sites than the following Germany. Together, 
traditional regions comprise 66% of the global trial sites.(25) 
Figure 7 represents, per country, which recruit more patients into clinical trials. North America has 
the higher values, followed by Europe and Oceania, which supports the previous information. 
 
Figure 7 Density of recruiting sites, per country inhabitant (2005). (25) 
The largest database concerning clinical research worldwide is ClinicalTrials.gov: a registry held 
by the United States National Institutes of Health. This registry lists and describes most clinical 
trials occurring worldwide, thus allowing more detailed assessments on the subject. Actually, there 
are 167456 studies registered on this platform, of which 85193 are in North America, 46440 in 
Europe, and 4482 in Oceania.(26). 
Nowadays, we are facing a shift to the “emerging regions”, namely Eastern Europe, Latin America 
and Asia. Although they lack tradition in clinical research, they offer conditions which are hard to 
compete with: lower operational costs, while still recruiting large numbers of patient very quickly. 
Besides, globalization of CROs, harmonization of guidelines and regulatory authorities from these 
emerging countries are enhancing this shift.(25) Due to lower need of investment, this countries are 
expected to grow even more in this field. 
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The proportion of trials of each phase per region is not equalitarian either: North America has a 
very high proportion of early-phase trials, and in Europe, Latin America and Asia there is a much 
higher proportion of late-phase and confirmatory trials(25). 
Globalization in clinical research can be addressed by two sides of the same coin: in one hand, it 
helps spreading medical knowledge and practice, and patients gain access to new therapies; on the 
other hand, regulatory supervision may not yet be adequate so there are some concerns with ethical 
issues and scientific conclusions drawn from the studies(25). 
Regarding worldwide investment and support context for clinical research, the situation is 
favourable (Figure 8). After the first market contraction in expenditure with pharmaceutical R&D 
of 2009, the market is forecast to slowly grow at 2,3% a year until 2016 (27). It is a slow growth, in 
which phase III trials will still dominate the market. 
 
 
Figure 8 Worldwide Pharma R&D Spend Forecast (billion dollars) – adapted (27) 
2.3. A NEW RESEARCH PARADIGM 
As the world life expectancy rises, populations become older and more demanding for new and 
better medicines. Until now, drugs have been developed through the “old” development model, but 
it is facing some serious challenges as these new demands emerge. This traditional model for drug 
development follows the model represented in Figure 9. 
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Figure 9 The traditional drug development model. (28) CIM – Confidence in Mechanism; CIS – 
Confidence in Safety 
 
A new “lead” compound (meaning a compound with potential to be developed) may be discovered 
through the most various ways: screening of natural products, synthetic design to match a certain 
target protein, computer-aided search in structural databases, or even by serendipity (29). After 
discovery, the lead must be further developed in order to enhance its chemical and pharmacological 
properties. In this phase the molecule is patented, and then starts the pre-clinical (also called “non-
clinical”) development (30). 
Pre-clinical testing is performed in vitro or in animals, with the purpose of identifying early 
pharmacokinetic (PK) and pharmacodynamic (PD) properties, and understanding the toxicological 
profile of the new drug (establishing minimum and maximum dose ranges, defining toxicology and 
establishing an initial safe dose to test in humans). Data must be transposable to humans by 
extrapolation (30). 
Traditionally, developing a new drug takes in average 12 to 14 years. After new molecules are 
discovered and identified as potential medicines, then follows pre-clinical and clinical evaluation 
(which takes most of the development time), and only after that the drug is approved and marketed. 
With this model, companies start investigating too many new molecules too early, which causes a 
molecular fallout: most of them fail after too much money had already been spent (28). This leads 
to a big productivity crisis in pharmaceutical companies. Comparing with two decades ago, 
companies now actually invest more in R&D activities and produce less molecules. Discovery of 
new molecules has not decreased; it actually increased due to development of the genomics, 
metabolomics and proteomics that followed the sequencing of the human genome. So, a new model 
was created to accompany the speed of discovery and face the new market needs (Figure 10). 
The new development model is focused on selecting candidates earlier in the development process, 
thus saving time and money. Facing the abundance of drug discovery, companies must have a clear 
scene of the pathology they are addressing and the involved mechanisms of physiologic response. 
After that, proof of concept should be obtained as early as possible, by testing whether or not the 
molecule works the way it is supposed to. Here is where most molecules should fail, and only the 
ones whose concept is proven must advance to further clinical development. 
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Figure 10 “The quick win, fast fail drug development paradigm” (31) 
CS – candidate selection; FED – first efficacy dose; FHD – first human dose; PD – product decision 
 
Because it supports earlier understanding of disease pathophysiology, this model enables earlier 
testing for biomarkers, determining subsets of patients which may respond differently to different 
drugs, thus supporting the future reality of personalized medicine (31). 
Both in Europe and the USA, there are governmental initiatives supporting the implementation of 
new paradigms. In Europe it is the IMI - Innovative Medicines Initiative, and in the USA the CPI - 
Critical Path Initiative. They both aim to improve and speed up the processes trough drugs are 
developed, evaluated and manufactured, by supporting innovative research projects. 
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2.4. CLINICAL RESEARCH IN PORTUGAL 
Data in clinicaltrials.gov shows that, from 46440 studies conducted in Europe, only 1052 happen in 
Portugal. In the map of Europe (Figure 11), it is possible to see that Portugal is still far behind from 
other western European countries when it comes to clinical trials. Especially comparing to 
Belgium, which is country approximately with the same size as Portugal, the number of trials is 
five times higher. 
 
Figure 11 Map of all studies in ClinicalTrials.gov - Europe (26) 
In Portugal, the number of submitted and authorised clinical trial applications has been decreasing, 
as shown in Figure 12. The historical lowest happened in 2011 with only 88 trials approved (32). 
This trend can only be reversed if something is done to address it. Otherwise Portugal will 
eventually vanish off the global panorama. 
Most clinical trials in Portugal are phase III (68% of total in 2012), whilst phase I trials are 
residual. Therapeutic areas with more ongoing trials are oncology, nervous system and infectious 
diseases. Most clinical trials are international and supported by multinational R&D companies, and 
there are very few trials of the investigator’s initiative. Approval times are very slow, especially if 
including the time taken by the hospital Abs. The three sponsor companies with more clinical 
assure 41% of the number of trials conducted (15).  
Transposing these characteristics into economic value, it means that there is a huge potential 
slipping through our hands. Investment in the area by international pharmaceutical R&D 
companies reached 36 million euros, and each euro invested in clinical trials has a revenue of 
1,98€. There are actually one thousand jobs created by clinical trials. The tendency to decrease 
activity in clinical research reveals a preoccupant loss of competitiveness, even more knowing that 
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if properly harnessed, the area could have a gigantic positive impact in the Portuguese economy 
(15). 
 
Figure 12 Number of submitted and authorized clinical trials by Infarmed, last updated on 31/01/2014. 
(32) 
Posted this, what can be done to improve the representativeness of Portugal in clinical research? 
First, one must not face the context of crisis and negativism with hopelessness. Being in the bottom 
must be faced as an incredible opportunity to grow (33). The study of 2013 from the Portuguese 
association of the Pharmaceutical Industry (15) proposes three initiatives that could be practiced in 
order to enhance market development in this field: they state that the current legislation must be 
reviewed for reducing times between submission and beginning of recruitment, clinical trial sites 
must be capacitated, and there must be incitements to involve more investigators into research. In 
fact, once that pharmaceutical R&D is increasing in the rest of the world, Portugal has no reason to 
be left behind. 
Portugal’s political environment is supportive to the development of clinical research. Dr. Paulo 
Macedo, the Portuguese Minister of Health, publicly recognizes clinical trials as a new source of 
funding that might be exploited in order to adjust the health expenses whilst increasing the access 
of the population to new medicines and interventions. With the recent approval of a new clinical 
trials law, he said that the goal was to “increase not only the number of clinical trials, but also their 
quality, their representativeness in terms on patients involved, and expand the number of phases” 
(34). 
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By investing more in clinical trials, Portugal can achieve better health indicators, early access to 
advanced treatments, better patient assistance, more scientific development, while creating jobs and 
reducing public expenses.  
This is the context in which Blueclinical, Ltd is created. 
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3. EXPERIENCE AS A CLINICAL RESEARCH COORDINATOR 
During the internship I worked as a clinical research coordinator in two different hospitals. 
Although the main functions dealing with clinical trials were very similar, the hospitals had very 
different contexts and integration of Blueclinical in the institution was performed differently. This 
chapter is subdivided in three subtopics, reflecting these aspects. First, I will describe clinical trial 
related activities in a sequential manner, which was similar in both hospitals, and then I will refer 
integration with CRP and office implementation differences, and finally I will focus on the training 
provided by Blueclinical during the internship. 
My main responsibilities as a CRC were the following: 
 Clinical Research coordination activities, according to applicable procedures, legislation 
and regulations, namely, ICH-GCP. 
 Point of contact for sponsors, “bridging” their contact with all hospital departments. 
 Collaboration in the development and implementation of the clinical research quality 
management system. 
 Financial agreement revision and implementation. 
 Collaboration in audit and inspection preparation activities and in the implementation of 
eventually necessary CAPA plans. 
 
As CRC I must provide support to all hospital’s departments and therapeutic areas, bridging them 
with the sponsors and with each other in what concerns clinical research. This includes not only 
clinical departments, but also supporting departments such as pharmacy, clinical pathology and 
AB. 
 
3.1. CLINICAL TRIAL RELATED ACTIVITIES 
3.1.1. FEASIBILITY 
From what I experienced in the internship, a hospital can be contacted for a feasibility study 
directly from the sponsor or CRO, or from Blueclinical CRP’s Back-Office. 
In the first scenario, the sponsor/CRO sends an email that contains minimal information about the 
study, such as the title of the protocol, name of the active substance and disease concerned. This 
email also contains a CDA (Confidential Disclosure Agreement), and asks if there is interest in the 
hospital to pursue the study.  
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The person contacted may be a physician or some of the CRCs. When the email is addressed to the 
physician, that person will presumably be the PI; when it is the CRC and the sponsor/CRO do not 
refer a name, the CRC job is to contact the head of the respective department. He may himself by 
the PI or may refer a colleague’s name. 
If the PI has interest in the study, he must sign the CDA stating that he will not disclose any 
confidential information contained in the protocol synopsis and the questionnaire that will be sent 
afterwards. At this point, I would inform the back-office of CRP that a new proposal arrived, for 
them to ask the sponsor if they would be interested in expanding it to more sites from the CRP 
network. 
The CRC sends the signed CDA to the sponsor/CRO and communicates that the PI is interested, 
and only after that the protocol synopsis and feasibility questionnaire are sent. This is the correct 
order of procedures, although I saw that sometimes the three documents came in the initial email to 
save time.  
As physicians are most of the time very busy persons, my role after receiving further information 
was to study the synopsis (and also some concepts from the therapeutic area concerned), to be able 
to explain it to the doctor very briefly. After that, the questionnaire itself must be fulfilled.  
There are online and paper feasibilities. Both of them are very extensive and time-consuming.  
After realising that these questionnaires were similar to each other in many aspects, I started to read 
the questionnaire before the physician and answer the questions I knew by myself: which facilities 
and equipment are available, in what times does the ethics committee and the AB approve a trial, 
how many audits were and how many findings, and other administrative data. That being done, 
very few questions were left to the doctor: only those concerning medical issues such as current 
practices, how many patients exist with the pathology, how many does he expect to recruit to the 
trial, and what are the main expected constraints. This method changes his perception about how 
extensive the questionnaire is and how much I could help him.  
What I realised trying to obtain accurate data about the number of patients with a certain pathology 
was that almost no department has databases of patients. Numbers answered in feasibilities were 
based mostly on assumptions, and so I usually advised doctors to underestimate the recruitment 
potential: it is better to have a small goal and achieve it than being too greedy and cause a bad 
impression in the end by recruiting less than expected. 
After all questions are answered, I would send the questionnaire to the sponsor, by email or just my 
clicking a “submit” button. After that I would again inform back-office that the questionnaire has 
been submitted. Then we must only wait from some feedback from the sponsor (the back-office is 
responsible for the follow-up of this processes). 
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Regarding the feasibilities that come to the hospital through Blueclinical CRP’s back-office, they 
can come already with a protocol or they can be proactive. Those who come with a protocol follow 
a similar scheme of those coming from the sponsor: there is an assessment of interest and a CDA 
that must be signed, and then there is a questionnaire to answer. The difference is that the site’s 
point of contact is always the back-office instead of the sponsor. Proactive feasibilities come in the 
form of a few questions (e.g. number of patients treated of a certain disease, what is the standard 
treatment for that disease in the hospital, etc.) and a brief interest assessment before the study 
design is known.  
When sponsors and CROs started contacting Blueclinical CRP for feasibility assessments directly, 
I noticed that sometimes there was duplication of entry points. Once, one of my colleague CRCs 
went to present the doctor the new study proposal coming from the back-office, and the physician 
already received it in his mailbox a few time ago. Most feasibilities come with a due date of one or 
two days to answer, which is very difficult for doctors since they are always on a busy schedule. 
When we arrive with these due dates and the doctor has already received the same feasibility before 
that may lead him to think we are being inefficient when that is not the situation. 
3.1.2. SITE QUALIFICATION AND SELECTION  
Answering a feasibility questionnaire may result in the site being selected or not to conduct the 
clinical trial. When the sponsor is deciding which sites to choose, they perform site selection or 
qualification visits to verify the conditions offered by the hospital, and whether or not the answers 
given on the questionnaire are true. 
I was present in at least two SSVs, one in CHVNG/E and other in HGO. In one of them, the 
sponsor already knew the site conditions and staff, because they worked together in the past, and so 
the SSV was conducted as a formality. In the other one, the sponsor had no knowledge whatsoever 
about the concerned department, the PI or any other team member. 
In a qualification visit, a sponsor or CRO representative comes to the hospital to assess the offered 
conditions. He will ask for the PI’s training and previous experience with clinical research (how 
many trials he had participated and for which indications), and request his Curriculum Vitae (CV) 
and ICH-GCP training certificate. It is evaluated whether the hospital has availability to perform 
imaging procedures or they have to be outsourced, for example, whether the department nurses can 
perform infusions or it needs to be done by specialist nurses, or whether pathologic anatomy is able 
to provide historical biopsy samples. Availability of materials such as a centrifuge, a refrigerator or 
a -20ºC or -70ºC freezer is also assessed. 
After the qualification visit, we must wait the answer from the sponsor on whether the hospital had 
or had not been selected to perform the trial. 
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During my internship, I noticed that most feasibilities that turn into a qualification visit resulted in 
the site being selected, except when the sponsor had chosen not to bring the trial to Portugal.  
Before being the back-office to follow up sponsor feedback, it was the CRC’s job to do that. In 
CHVNG/E, it was needed to “catch up” some feasibility processes which were lost and whose 
feedback was unknown. Our action was to call the sponsor and ask directly what happen with that 
specific trial. Sometimes, the sponsor had cancelled the trial globally, but the most common is trials 
getting “shuttled out” from Portugal and still happening in the other parts of the world. This was 
some evidence I saw of the premise of Portugal becoming slightly apart of the global panorama in 
clinical research. 
 
3.1.3. BUDGET NEGOTIATION AND SUBMISSION PROCESS 
In this section I will include all procedures since the sponsor informs the site that it has been 
selected through site activation. I performed several submission processes alone in CHVNG/E, but 
in HGO I did not have the opportunity to do so within the time frame of this report. 
After receiving confirmation that our site was selected to a specific trial, I would start gathering the 
required documents and negotiation of financial contracts. In first place, the sponsor needs 
approval from INFARMED, CEIC and CNPD. For the initial submission, a set of documents are 
required from the site: the PI CV, protocol signature page signed by PI and declaration of facilities. 
GAGIC provided a template for CVs to be collected focusing previous experience in clinical trials 
and ICH-GCP training. Protocol signature page is provided by the sponsor. The declaration of 
facilities can be in a sponsor template, and this case there is one for the head of the department to 
sign and another one to the head of the pharmaceutical services. With GAGIC, we created a 
template of our own in which all authorisations are provided in one declaration only: it states the 
facilities, equipment and human resources available for the trial, and then all head of departments 
involved sign below in agreement. This way it is ensured that every required service was involved 
in the process since the beginning, and it spares one declaration. My job was to go to all the 
required departments, remember them about the study and the collect signatures. If the department 
agrees with the trial, its head would sign the declaration. If it does not, one of two things could 
happen: if it is key service like pharmacy the trial may not be able to proceed; if it is a 
complementary service like imaging these procedures can be performed in an external facility. 
After several meetings between Blueclinical and CEIC, there are two documents that are also 
requested by CEIC in order to clarify the CRCs position in the hospital and ease the approval. One 
of them is for Blueclinical to authorise the participation of one or more CRCs in each trial, and the 
other one is for the president of the AB to sign with the same purposes. To avoid the congestion of 
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the AB, there is one document for the AB to sign that delegates this function to the office 
coordinator. I must provide these to the sponsor along with the initial “submission package”. 
After approval from INFARMED, CEIC and CNPD, or immediately after site selection (as the 
sponsor agrees) the submission process for the hospital can begin. In CHVNG/E there were 
verification lists of all the documents that must be included in the submission dossier to be 
approved by the AB. There was one for clinical trials (with medicinal products), one for clinical 
studies (with medical devices) and other for observational studies. The following tables describes 
the general structure of a submission dossier for a clinical trial: 
Table 1 List of required documents in a submission dossier for a clinical trial 
Title Description 
Cover Letter 
A letter written in Portuguese, addressed to the AB, referring 
EudraCT number and protocol title and number, requesting 
approval of the trial. It must be signed by the sponsor. 
Index Identification of all documents, with version/date. 
Contact List Sponsor or CRO contacts. 
Protocol Updated version, signed by the sponsor and PI 
Protocol Synopsis In Portuguese 
Site Facilities Declaration 
A template provided by GAGIC describing all facilities, 
equipment and human resources available for the trial, and 
including the signed authorization of the head of all departments 
involved (e.g. Pneumology, Pharmacy, Imaging and pathology). 
Investigational Product 
Circuit 
Template provided by GAGIC; defining who is responsible for 
supply, reception, storage, prescription, preparation, dispense, 
administration and devolution of the IMP. 
Principal Investigator’s CV In the GAGIC template. 
Financial Agreement 
At least two copies; sponsor’s template until CRPs is not 
available, with the final result of negotiation. 
Insurance Policy  
CEIC Approval If applicable 
INFARMED Approval If applicable 
CNPD approval If applicable 
Sponsor Declaration 
When CEIC, INFARMED or CNPD approvals are not yet 
available, this declaration states that the sponsor will not initiate 
the trial before this approvals are collected. 
 
The investigational product circuit and medication feasibility declaration are two templates which 
needed to be completed in the submission phase. They basically stated what are the IMPs involved 
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in the trial and who are the responsible persons/services for handling them (supply, reception, 
storage, prescription, preparation, dispense, administration and devolution).  
At this phase, the PI must define the investigation team for the trial: who will be the responsible co-
investigators, nurses, pharmacists and study coordinators, and must attribute a defined percentage 
to be in the financial protocol destined to each one. As in this case CRCs are paid by Blueclinical, 
they cannot receive a percentage and must appear on the division as receiving 0%. 
One of the most important things in this phase is the negotiation of the financial protocol. In the 
first times I did this, I would receive a previously drafted contract from the sponsor. Then I read the 
document and checked with the protocol if every procedure is contemplated and if the value is in 
accordance. To check payment per procedure was really time-consuming but it was an objective 
task that I could achieve. To assess if each procedure was being underpaid was tougher. I was 
provided with big tables of standard values for some procedures that I could use as comparison. 
Although, some procedures had an established value as a pack (e.g. height, weight and vital signs) 
and the protocol only required a part of that; other procedures were not contemplated at all. 
Another way of doing this was to estimate the time the doctor or the nurse would require to do the 
procedure and pay it according to their salary per hour, but I found this very uncertain.  
Negotiating financial contracts was for me a very difficult task at the beginning, because I lacked 
knowledge on this field. I was able most of the times to estimate if the amount was or not fair. 
Nonetheless, when I found a trial to be underpaid, I felt like I could not request a higher payment 
because there was no solid support behind my request. All negotiation of financial contracts is now 
centralised in the back-office, which is for me a “relief”. In that way I know that the person 
responsible can certainly do a better job than I did, and that will save time for ongoing clinical 
trials and recruitment. 
 
3.1.4. INVESTIGATOR MEETINGS 
During the internship, I had the opportunity to attend two investigator meetings. The first meeting I 
attended was in Coimbra, Portugal. It was organised by Boehringer-Ingelheim for the trial 1200.55, 
relating to a new molecule developed to treat lung cancer. The second one was in Barcelona, Spain, 
organized by AstraZeneca for the SELECT-1 study, also in the therapeutic area of lung cancer. 
In investigator meetings, the trial is presented by the people that are directly involved in its 
conception. This is great because they have more insight in the trial than CRAs do, and they are 
speaking for a large number of site personnel. So, they can make the correct information reach a 
high number of sites, as they are also more prompt to answer specific questions. 
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In both meetings, I had the opportunity to meet investigators and study coordinators from other 
sites and other countries. I sat next to the other Portuguese people, due to ease of communication, 
and I actually enjoyed getting to know those from other sites doing the same as I do while 
discussing the themes being presented. After attending an investigator meeting, I realised that I 
knew more about the concerned trial when comparing to others I only got on-site training. 
3.1.5. CLINICAL TRIAL INITIATION 
After all approvals are gathered, it is time to prepare initiation. The sponsor will send us links to 
perform e-learning trainings (in general subjects as ICH-GCP, and in trial specific subjects). After 
those trainings are complete the IVRS or IWRS systems are activated and each team member 
receives login credentials. The same happens with CRF systems. The sponsor triggers the dispatch 
of trial materials such as medication and collection kits that will arrive to the site in this phase. 
In the beginning of my internship, in CHVNG/E, I would create flowcharts summarizing the 
procedures to perform before, during and after each patient visit. This was a nice exercise for me to 
learn more about the procedures, although this was very time-consuming and later on I stopped 
creating flowcharts. Nevertheless, we continued creating preparations for each visit with the topics 
that must be written in the patient file. 
In HGO, there is fewer time available, and no checklists were created. 
A SIV is scheduled, in which a sponsor or CRO representative comes to the site to train the team in 
a more personal approach (as they already did the e-learning trainings). I was present in three SIVs. 
These are useful to resolve any doubts we may have and to get to know the protocol with more 
detail and in a more adapted approach to the hospital’s reality. This is when the responsibilities of 
each team member are defined and the delegation log is fulfilled and signed by the team members 
and the PI. As the team is gathered, the SIV is a great opportunity to manage pending issues such 
as the collection of the team CVs. 
After the team completes all trainings, all materials arrived to the site and everything is ready to 
start recruiting patients, the sponsor activates the site. We receive an email stating that and we can 
indeed start recruitment. 
 
3.1.6. RECRUITMENT STRATEGIES 
By seeing the reality of recruitment in two different hospitals, I have two different views on 
recruitment strategies. 
In CHVNG/E, especially in the oncologic pneumology department, our main recruitment tool were 
the “group meetings”. These meetings happened every Monday morning, and all physicians of the 
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department were gathered to discuss their medical cases, irrespective of clinical trials. One of the 
four CRCs would always be present in each meeting. Our role was to be there for the whole 
meeting paying attention to the patient characteristics, and constantly comparing them to inclusion 
and exclusion criteria of the open trials in order to alert the doctors when an eligible patients comes 
up. This strategy was not always efficient. It is hard to understand everything said by the doctors 
without losing the track, because they know their patients and most of the times do not list all the 
criteria we need to know. Said that, the result of many group meetings was zero patients recruited 
versus a lost morning with other work left to be done. By the time we realised that group meetings 
were not such a good strategy, we started reading on Fridays all the patient files that were to be 
discussed in the next meeting. That was a better strategy in the aspect that we could be more 
focused on the criteria for entering each trial. Although we noticed that the doctors did not pay 
much attention to our notes in the Monday, and we needed to remind them anyway. In the internal 
medicine department, one PI provided us with a big list of patients followed there for us to help 
identifying patients. It is difficult to ascertain all criteria just from searching in the hospital’s 
informatics systems. Overall, I saw recruitment goals as a statistic number that may or may not be 
achieved. 
When I arrived to HGO, I faced a completely different situation about recruitment. At first, I 
realised that doctors would become upset and frustrated if they are unable to achieve recruitment 
goals. They take that number as a personal commitment and engage to pursue it. Recruitment 
strategies also vary from department to department. In Cardiology, I noticed that my colleague had 
a good relationship with the doctors and they were able to talk more openly about everything, 
including obviously clinical trials and including patients. She worked most of the time in a meeting 
room of their department, which contributed to the good relationship created, and which allows a 
huge proximity to all staff and to the patients. In the two clinical trials with more success in 
recruitment, patients should be hospitalized at screening. Hospitalisation ward of cardiology is 
physically really close to that room, and so there is a high level of proximity with all intervenient in 
recruitment. She would know the conditions of patients in there and if one could be included, she 
would go to the responsible doctor and ask if inclusion in the trial could be considered for the 
benefit of the patient. These clinical trials in Cardiology have wide inclusion criteria. This is not the 
only reason, but in other services the recruitment is not so high. When patients must be recruited 
from outpatient visits, the job is a little harder. Only doctors know their patients, and so it is more 
difficult for us to help. Strategies here could be similar to those used in CHVNG/E. What I noticed 
was that doctors have more motivation to recruit and to achieve recruitment goals. 
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One effective method is to establish a recruitment plan prior to the trial initiation, defining what 
strategies will be used to recruit patients. That would ease the process during the trial and speed up 
recruitment. 
Patients spotted using these strategies are considered “identified”. 
 
3.1.7. TRIAL SPECIFIC PROCEDURES 
After a patient is identified, a screening visit is appointed. Each protocol is different from the next 
one, although some things are common. I will only focus the common procedures. 
INFORMED CONSENT 
In the screening visit, the first procedure is always to explain the study to the patient in terms he 
can understand. It is usually the doctor who explains this, although sometimes I was there too to 
help clarifying the information. The ICF is useful to guide the explanation. This explanation is 
supposed to be a discussion with the patient and he should be encourage to ask any questions he 
may have. I have seen patient react very differently when we propose them a study: some patients 
are very submissive to the doctor opinion and often say “If you say so, doctor, than I will do 
whatever you find the best for me”; other patients hear the word study and immediately start 
picture themselves as guinea pigs and will not enter the study, even if we clarify the conditions and 
safety requirements of studies. I have seen patients making up excuses not to be available for the 
appointments when in fact they are scared, I have seen wives not letting their husbands participate, 
I have seen patients who are just afraid of needles, and I have even seen patients who did not enter 
a study because their family doctor told them not to. One thing I realised was that the most 
confident the doctor is with the trial and explaining it to the patient, higher is the probability that he 
accepts. And if the doctor is not comfortable, it is our job to “train” him so the next time he will be. 
After the explanation, if the patient agrees to participate, we provide him two copies of the ICF for 
him to sign. Both should also be signed by the responsible investigator. One copy is to be archived 
in the patient file, and the other one must be kept with the patient. Only after this step is complete 
we can proceed to the visit specific procedures. 
SCHEDULE OF ASSESSMENTS 
Each protocol defines a specific set of assessments to be performed at each visit. According to the 
therapeutic area there could be more or less procedures, such as spirometries, electrocardiograms 
(ECGs), quality of life questionnaires, among others. Although, some of them are standard and 
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must be performed in almost every visit, including a set of assessments for the nurses, other for the 
doctor, and other for technicians when applicable. 
The procedures for nurses are usually the measurement of vital signs, height and weight, collection 
of blood samples, and when applicable to train the patient with self-injectors or other devices. From 
what I saw, all these procedures are normally to be performed before the medical examination of 
the patient. In CHVNG/E there were also the nurses who got the patients to answer the 
questionnaires. 
After that, the patient is seen by the doctor, which performs his usual evaluation plus the 
procedures required by the protocol.  
If the protocol requires imaging procedures, those should be scheduled by the CRC according to 
the timings defined in the protocol. 
In the two hospitals, patient visit scheduling and appointment was performed differently. In 
CHVNG/E, the patient appointments were schedule as any other patient; when he arrived, he must 
wait for its turn, then go the nurses room. After that, he would wait for the local lab results to be 
available if needed, and only after that he is seen by the doctor. This method seems logical, but 
many times it made me wait a lot of time and keep asking the secretary about how much time was 
it left to the appointment. In HGO, patient visits are scheduled by the CRC only, according to the 
doctor’s availability. When the patient arrives, it is the CRC that would receive him and ask how he 
has been feeling, and then guides him to the nursing room and gets the doctor to come see the 
patient. Although, it is important not to forget that this comparison is between two different 
therapeutic areas and not all approaches are transposable. 
IXRS SYSTEMS 
In every visit, I or any of my colleagues must contact IXRS, meaning it can be IVRS – by phone, 
or IWRS – via web. These systems allow the registration of the patient status in every visit and the 
allocation of blinded medication. Contacting IXRS every time is always similar: whether I must 
dial a phone number of enter a website, I will be prompted to confirm the patient number, date of 
birth, confirm the visit number and if there is any medication to be dispensed. After that, the system 
provides the medication codes that must be dispensed and sends a confirmation e-mail to the team 
that must be filed in the patient file. Medication codes must be written in a prescription sheet that 
would be taken to the pharmacy to retrieve the medication itself. 
Although this seems like a linear procedure, there were differences between the two hospitals. In 
CHVNG/E, I would only contact the system after the doctor already examined the patient and 
confirmed he must proceed to the next visit. After the appointment, I would get to the pharmacy as 
fast as I could because the patient was in the hospital just waiting for me to come with the IMP so 
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he could leave. In HGO, as the CRCs are the first persons to check on the patient, we would contact 
IXRS and get the medication while the patient is in the nursing room or waiting for the doctor. Of 
course we only did this if the patient seemed healthy and without complaints, depending on the 
disease considered (in oncology, the doctor always examines the patient before IXRS is contacted). 
The method used in HGO results in a faster visit, allowing for more visits to be performed in the 
same day. If there are more than one patient in the same department in the same morning, in 
CHVNG/E they would be attended sequentially, and in HGO they would both start by nursing 
procedures, the CRC would contact IXRS and bring medication for both, and then the doctor (if it 
is the same) examines both of them sequentially. 
BIOLOGICAL SAMPLES PROCESSING 
Blood and urine samples must be collected in almost every visit. Per protocol, they could be 
analysed in the hospital’s local laboratory or in the sponsor’s or CRO central laboratory (or both). 
For central laboratory analysis, the blood is drawn into specific collection tubes that comes into 
small boxes called “kits”. These kits also include transfer tubes, to where the blood plasma must be 
transferred after the sample is centrifuged, and the requisition that must accompany the samples 
when they are sent to the central lab via courier. 
In CHVNG/E I never processed any patient samples. This was done by the nurses in oncologic 
pneumology department, or by the clinical pathology department. In HGO I processed samples 
almost every day, and I found out I actually liked doing it. For each protocol there is an associated 
lab manual describing what needs to be done and it is not hard to follow. Most samples need to be 
centrifuged, but others do not. Sometimes I was required to perform blood smears, which was quite 
a challenge at the beginning because I could not get them right. After all samples were properly 
separated and identified, they are put into specimen transport bags to be sent to the central lab. 
They can be sent at ambient temperature, refrigerated with frozen packs, or frozen in dry ice. 
Frozen samples were normally sent once or twice a month in dry ice. For the time they are in the 
freezer, data loggers are required to ensure the correct storage temperature. When the sample is in 
the package and ready to go, I contact the courier and schedule the pick-up for that day. 
REGISTRATION OF DATA IN THE PATENT FILE (PAPER OR ELECTRONIC) 
During or after the visit, the doctor must register everything in the patient file. In CHVNG/E, I 
dealt with mostly paper files, and in HGO the files were all electronic. In clinical trials, “what is 
not written did not happened”. The completeness of the visit records will reflect the quality of the 
visit procedures themselves, and will be the support for a well completed CRF. 
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Doctors are not prepared to register all the information required for clinical trials as their daily 
practice. To ensure this registry, in CHVNG/E we created checklists with all topics that must be 
written, and in HGO we were next to the doctors telling them what to write. 
In the screening visit, it must be recorded the hour in which the patient signed the ICF, and what 
was the version. All inclusion and exclusion criteria must be checked, and that has to be written. It 
is important to collect and register the time blood was drawn, vital signs were measured, or the 
ECG was performed. If the patient must rest for 5 minutes before assessing his blood pressure, it 
must be registered that the patient rested for 5 minutes before the measurement. All concomitant 
medication taken by the patient from the moment of informed consent (or previously when 
required) must be registered, including start date, end date, dosing and therapeutic indication. To 
remember what to advice to the doctor to write, I try to think in the CRA’s point of view: he can 
only know if we complied with the protocol if that it is written.  
AES AND SAES 
In the screening visit, every condition the patient had must be assessed and recorded as baseline 
conditions. From that time forward, all new adverse events (AEs) or worsening of baseline 
conditions must be registered in the patient file and reported to the sponsor in the CRF. If the 
events meets the seriousness criteria, it is a Severe Adverse Event (SAE) and it must be reported in 
24 hours, in the CRF or using the sponsor paper SAE form, depending with the protocol. When 
gathering information on AEs, it is important to collect start and end date, intensity, causal 
relationship with the IMP or study procedure, and outcome of the event. Intensity may be graded 
just as mild, moderate or severe, or it can be graded using the CTCAE grade (Common 
Terminology Criteria for Adverse Events). CTCAE has five levels, classified as following: grade 1 
– mild; grade 2 – moderate; grade 3 – severe; grade 4 – life-threatening; grade 5 – dead. 
It is very important to collect information on AEs and SAEs correctly, as it will be crucial to the 
benefit-risk analysis of the IMP. 
COMPLIANCE VERIFICATION 
In every visit, patients must always bring all the medication they have in their possession. Counting 
the number of pills (or injections, etc.) is the only way to know whether the patient took the study 
drug or not. If more pills are returned that those expected, that means the patient missed doses. If 
he returns less pills that expected, he may have taken more than it was supposed to or he may have 
lost some pills. I always encourage patients to be compliant and to return all medication, although 
sometimes they forget it. The number of returned pills must be registered in the patient file, but the 
ultimate responsible for accountability is the pharmacy. 
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CRF COMPLETION 
Every patient visit has a corresponding CRF page that must be fulfilled. CRFs may be in paper or 
electronic, although I only worked with electronic ones. There are several platforms used by 
sponsor, designed to collect the information required for the statistical analysis and retrieve the key 
information on the study. CRFs must be completed as soon as possible, as it is easier to remember 
data right after the visit. 
CRFs are all similar, despite of the platform used. They ask for the visit date, measurements, 
results, timings, AEs and concomitant medication. The biggest difficulty in completing CRFs in 
CHVNG/E was due to the illegible handwriting of most physicians. It took a lot of time to decode, 
and some brainstorming with my colleagues occasionally. Electronic records are much easier in 
that aspect.  
After data is introduced in the CRF, it will be reviewed by the CRA and by the study data 
managers. If they detect any discrepancy, they launch queries for the site to resolve. The best way 
to avoid queries is to ensure a good registration of data in the patient file. Although, there are 
always queries and their management takes some time and effort. Data managers do not understand 
want happens in the visits and are very strict to the protocol and not much open to daily hospital 
practices. 
PATIENT REIMBURSEMENTS 
Patients in clinical trials must not have expenses incurring from their participation. So, expenses 
related to transport to the hospital and food in the visit days are all reimbursed by the sponsor. In 
both hospitals, I must gather the receipts from the patients, check if the dates match the visit dates 
(or the days before, if it is a receipt from gas or public transportations) and register them all to keep 
tracking. Reimbursement can be done by various ways. The most common is to deliver the receipts 
to the CRA, which will bring the money in the next visit, although none of us likes to carry money, 
because there is always the risk of losing it. In HGO, the hospital has a system in which the patient 
fulfils a form with the annexed receipts, the hospital bills the sponsor, and then the money is 
transferred to the patient or he could get it from the hospitals treasury.  
MAINTENANCE OF MATERIALS’ STOCK 
During the studies in which samples are sent to a central laboratory, collection kits and shipping 
documents and boxes are materials we must always have available in the site. In CHVNG/E we 
created excel tables to register every time a kit arrived, was used or destroyed, and the sheet 
automatically displays the number of kits available. As expiration dates approached, we configured 
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email alerts to remind us to destroy the kits and avoid they are used expired. This worked very 
well. Although, in HGO there was no table for controlling kits. They are all in a cabinet where we 
can see them, and we can know how many kits are available, but this system is less rigorous than 
the control performed in CHVNG/E. When we realise the material are running low and order more, 
sometimes they do not arrive in time. In these situations “repeat” and “unscheduled” kits must be 
used, choosing the appropriate tubes for each visit according to the lab manual. In the beginning, 
these issues bothered me a little bit because in CHVNG/E there was a great control of stocks. The 
truth is I became more prompt to solve problems after dealing with this situation. I created one 
excel table similar to the ones used in CHVNG/E for the HGO’s pneumology service. Although, it 
is in Cardiology that more samples are sent and more materials spent: the volume is so high that it 
is a table is not a practical method of control. My suggestion was to define a specific day in the 
week to verify materials and order more as necessary, ensuring these situations are minimised. 
3.1.8. STUDY CLOSE-OUT 
After all patients finished the study, the sponsor will eventually perform its close-out. I assisted two 
close-out visits, where the CRA comes to the site and verifies all documents, ensuring the dossiers 
can be closed and remain archived during 15 years. As they cannot be moved, and they can be 
subject of audits and inspections, all documents must in place and compliant with applicable laws. 
In a close-out visit, we must provide the CRA the investigator site file, patient files, and all source 
documents from clinical visits and from the pharmacy logs. In this visit, the CRA would collect all 
unused materials form the site, such as kits, ECG machines, computers and data loggers. 
All trial dossiers are marked as closed, and should be archived according to the conditions stated in 
ICH-GCP. 
3.1.9. MONITORING 
Each clinical trial has a monitor or CRA, which is the responsible person from the sponsor or CRO 
to ensure that we, in the site, are complying with the protocol, ICH-GCP and safeguarding the 
rights of subjects. For this, CRAs perform Source Data Verification (SDV): in each monitoring 
visit, they compare the data in source documents to the data registered in the CRF. 
To prepare a monitoring visit, I must ensure that all CRFs are up-to-date, the queries I could 
resolve were addressed, and the patient files and ISFs are organised and up-to-date. When the CRA 
comes, I must provide him with all the documents so he can do SDV, and I and the PI must be 
available to resolve any identified issues and explain eventual situations. 
CRAs often are a great help for the site staff, even out of monitoring visits. They are almost always 
available by phone and prompt to help us and answer our last-minute questions. 
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3.2. ACTIVITIES RELATED TO CLINICAL RESEARCH OFFICE 
IMPLEMENTATION AND INTEGRATION WITH BLUECLINICAL 
The state of integration of Blueclinical and the office in the hospital structure was completely 
distinct from one hospital to another. In CHVNG/E, GAGIC was fully integrated in the hospital 
structure, although there were still some administrative constraints. A few days after beginning the 
internship, I had a mechanographic number, access to the hospital’s Wi-Fi network, and a set of 
two white coats. When addressing a person from the hospital I never met before, I would say 
“Hello, my name is Daniela and I am from GIC” and most persons in the hospital would recognise 
GIC as an entity. In HGO, only a small number of doctors know there is a company named 
Blueclinical who has a partnership with the hospital. CIC is not recognised by anyone. When 
addressing someone new, or that person would knew my colleague and I would say I work with 
her, or I would have to explain the history from the beginning. After two months in the hospital, I 
still not have a mechanographic number. I wear a white coat, but because the staff in the clothing 
department facilitated the process. 
After this brief context, I state below some activities I performed not related to a specific clinical 
trial. 
3.2.1. HISTORICAL DATABASE OF STUDIES AND PAYMENTS 
One of the first tasks I did in CHVNG/E was to elaborate the history of clinical trials and 
observational studies that occurred after 2008. There was one table to register general information 
about each trial in that period, and that was another one that I created to collect payments data. The 
purpose was to establish a “baseline condition” to allow comparisons between before and after the 
partnership. Data was very disperse through the hospital and it was not easy to gather. Most of the 
data we could retrieve from the financial department, which had saved some information about the 
studies involving payments. In the pharmaceutical services there was also a control table, but only 
about clinical trials requiring medication (there was no data on observational studies). Some other 
information was in the hospital’s annual report. The rest of the information we retrieved from the 
lost dossiers and papers in the clinical services. In the end we had created an excel table compiling 
all sources and that is presumably complete. 
Besides that database I created an excel document to control payments only. Even if the partnership 
increases the number of trials, that is no guarantee of an increase in the income and so we need to 
control that too. Again, some information I got from the financial department, but it was not very 
correct as the same trial may have different names in different documents, and it was a little bit 
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confusing. Some clinical departments had tables of their own. Most data I got from listing sponsor 
names from the studies database and questioning each one about which payments happened after 
2008. That is time consuming for us and for sponsors, and so when I left CHVNG/E this payment 
history was still incomplete. 
In HGO there was already a historical database, although not very complete, which was created by 
the existing structure to support research. 
3.2.2. PRESENTATIONS TO THE CLINICAL SERVICES OF THE HOSPITAL 
In CHVNG/E, the partnership with Blueclinical and the recently formed GIC were presented to the 
departments in a formal meeting that occurred in July 10th. This presentation was essential to the 
divulgation of Blueclinical, to let the doctors know who we are and how can help them. As the 
partnership is between one public and one private entity (and these are not well-seen in the 
Portugal’s present) it is also necessary to break some myths and to clarify what both parts are 
winning with this.  
The GIC strategy at the time was to perform, beyond this one, a presentation to each clinical 
department (where more doctors could attend and the discussion could be more personalised). We 
decided with GIC’s coordinator to start supporting the services only after the office had been 
individually presented to the service, from doctor to doctor. The true is that the doctor to doctor 
approach works better, although they all have very complicated agendas and it was very hard to 
conceal everyone’s availability to schedule some of the meetings. When I left CHVNG/E, in the 
end of February, GIC was still lacking presentation to a few departments. 
My experience told me that these individual meetings are not feasible. We ended up helping 
departments before they met us formally, and there were trials in which we could have entered a lot 
earlier if it was not for this. Although, I understand their importance and I would suggest to try to 
condense two or three departments at each time; or to open the initial formal meeting to all the 
hospital community. 
During these meetings, doctors always seem more interested in their small and casuistic studies 
than in clinical trials. Many of them never performed trials, and so they are more interested in 
statistical support and medical writing. 
3.2.3. QUESTIONNAIRE OF INTERESTS 
The questionnaire of interests is a major tool in the development of Blueclinical CRP: It is an 
electronic questionnaire that must be sent to every doctor in the network, which contains basically a 
list of therapeutic indications. Doctors must choose those indications they would like to investigate. 
With that information, Blueclinical would be able to characterise the interests of Portuguese 
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doctors and attract to the hospitals clinical trials of their interest. What happens now is that 
Portugal must conform with the trials the sponsors decide to bring to Portugal (which are normally 
those harder to recruit, or those which are too complicated and do not succeed in other countries). 
In CHVNG/E, the link to the questionnaire was initially sent by emails using institutional mailing 
lists. It did not succeed because most doctors do not use that email. The next strategy was to print 
questionnaires and, using a list of all doctors as control, going personally to each doctor to get the 
answers.  
In HGO the link was also sent by email, first to the institutional emails of physicians, and then to 
their personal ones. After a few complication, we now have also a control list with all the names 
per department. There is less time available to perform these tasks as the volume of clinical trial 
visits is higher. Although, despite the few responses gathered, the questionnaires already led to a 
success case: there was one new trial for venous thromboembolism proposed to the cardiology 
department; from the database of responses we saw that two internists were interested in that area, 
and now the team is composed by both departments.  
3.2.4. WEBSITE 
One objective of CRP is to have information about each office in the hospital’s internal and 
external website. As there is no template available yet, every CRC gave his contribute to the 
construction of the contents. In CHVNG/E, the information is already available in the internal 
website. 
Generally, the information covers: important news and information; GIC organisation and contacts; 
SQIC; frequent asked questions (by patients, physicians and sponsors); and a list ongoing of 
clinical trials. What is displayed in the internal and external website depends on the applicability: 
contents directed to patients or sponsor must be available in the external platform, as contents 
which are specific for doctors may be only available in the internal platform. 
I believe that having a website is a useful asset, as the partnerships are new and not very 
widespread, both inside and outside the hospital’s facilities. 
3.2.5. RESOLUTION OF ADMINISTRATIVE CONSTRAINTS 
The implementation of a new office in a hospital is a difficult task. Hospitals are rigid structures, 
and trying to change their methods will cause some constraints. That happened when trying to 
implement fee exemptions for trial patients, finding a way to reimburse patient expenses through 
the hospital, and trying to remove duplication of ethical approvals. 
Participants in clinical trials must not have any expenses incurring from the trial; that includes user 
fees in consultations and examinations. In most hospitals they tell us there is no way to exempt the 
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subjects of the payment of those fees (that happened in CHVNG/E). In HGO there is an 
administrative code that was created to allow that exemption. I tried to understand how that code 
was created, as exemption is a legal requirement and must be implemented in all hospitals of the 
network. From what I understood, the clinical director of the hospital must authorise the creation of 
the code by the department of informatics, and then the exemption code is created in the same way 
as other legal exemptions (e.g. blood donors, oncology patients, low income subjects).  
Relating reimbursement of patient expenses, the most common method is to deliver the receipts 
and receive the money through the CRA, having both of us to carry money. As this is somewhat 
risky, the ideal procedure would be the hospital to bill the value of the expenses directly to the 
sponsor. Then, the sponsor would pay the hospital, which will in its turn deliver the value to the 
patient, in physical money or by bank transfer. This method is possible in HGO, although they 
require a lot of data from the patients, such as bank account and several other numbers.  
Other issue that could be avoided is the duplication of ethical assessments. Clinical trials must 
always be approved by the national ethics committee (CEIC). Clinical studies follow the same 
procedure after the law 21/2014 became effective, but previously they must only be approved by 
local ethics committees just as observational studies. The logical situation would be to never 
duplicate assessments, and only studies not undergoing CEICs revision must be submitted to local 
ethics committees. In CHVNG/E we were able to eliminate this duplication, but in HGO it still 
exists and it is one big constraint hindering approval times.  
 
3.3. ADDITIONAL TRAINING 
During the whole internship I performed several trainings in e-learning platforms and also face-to-
face training provided by the company. 
The first training was only one week after the internship interview, when I had not yet started the 
internship itself. In that training I was taught a lot the Blueclinical project and ambitions, and 
specifically about quality management, effective communication, and values and standards.  
During the first days in CHVNG/E, I needed to complete several e-learning trainings about ICH-
GCP, informed consent process, InForm (a CRF platform), fraud and misconduct, AEs and SAEs 
and sample shipping. I was already familiarised with some of the concepts from my academic 
background, but nevertheless they were useful to remind some ideas and to have a proof of training 
as they provide certifications.  
During the course of the internship, I attended several training sessions provided by Blueclinical. 
Many of them were presented by the colleague working directly with that specific subject, what 
was a very enriching experience because I felt more motivated to ask questions and collaborate 
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with the discussion. These trainings covered applicable laws and regulations to clinical trials and 
medical devices, specific day-to-day subjects of a CRC life such as recruitment practices, ICF, 
screening and randomisation, overviews of procedures from feasibility to close-out. I also got 
insights on data management and the processing of human biological samples in clinical trials. 
Everything is recorded in a training log, whose template is provided by Blueclinical. 
Apart from general training, each clinical trial protocol requires the completion of a set of trainings 
in order to become a member of the study team and to receive credentials for study platforms. 
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4. DISCUSSION 
Having the opportunity to contact with two different hospitals was a very enriching experience. 
When I initially faced the change of hospitals I was not so excited to leave the team I knew and my 
comfort zone, but I now see it as a positive change: I feel more independent, I learned a lot about 
patient visits and other procedures, and I now have a comparative insight otherwise I would have 
not. Overall, the change made me grow, professionally. 
In the beginning of this internship I was very insecure of my own. For example, I would ask for 
someone to review my emails before sending them all the time and I was afraid of answering phone 
calls. Slowly, with encouragement and by gaining experience, I became more autonomous and 
more confident of myself, and I started taking responsibilities of my own.  
In CHVNG/E there were four CRCs, myself included, and we had a very supportive working 
environment. The work was divided between the four of us, and at the end of most days I felt like I 
could achieve my objectives for the day. I helped directly in a few patient visits, but most of the 
time I dealt with submissions and administrative tasks. We divided the trials between ourselves, 
irrespective of their status, and so I ended up learning more about submission processes than 
patient visits.  
The background from the previous year of the master’s course provided me a solid knowledge 
about the contents I faced in the internship later on. Although in the beginning I did not know 
exactly what the functions of a CRC were, I realised after some time that I actually knew how to 
get things done in theory. After some time living the practice, it was quicker to learn about the roles 
I was supposed to perform. The medical contents I learned in the BSc in Biomedical Sciences were 
also useful, as I could have a better understanding of the mechanisms of disease implied in clinical 
trial protocols. Without any doubt, I was able to understand what it is to be a clinical research 
coordinator during the internship, which was my main goal.  
 
Despite how much I learnt with this internship, there was some subjects I have never dealt with. I 
never performed submissions or helped directly with clinical studies of medical devices. I never 
had any audit or inspection during this time frame also. I believe being involved in a quality audit 
or inspection is a big lesson for someone working daily with the procedures being verified.  
There were several procedures that I found to be less efficient during the internship, most of them I 
already focused in the previous sections. The main one is related to the analysis of financial 
protocols in submission phases. I feel like I needed to perform a task I was not sure how to 
perform, and I ended up taking a lot of time doing it that had no revenue. Happily that is already 
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solved, as there is one person in the company responsible for negotiating contracts for the entire 
network. 
Other aspect I did not felt so comfortable about was the request for archiving fee to the sponsors. 
Presently that is not done, but in the beginning it caused me some constraints. Initially I was though 
to request the sponsors to directly contract an archiving company. Some sponsors could accept this, 
but one of them who could not suggested us to request an archiving fee, which was higher than the 
effective cost of the archiving company. I agree with the procedure of requesting a fee and I 
understand that we need to evolve with experience, as a company. What I disliked was to lack a 
justification for the amount I was requesting, which let me uncomfortable. Besides, I dealt with one 
sponsor that had a trial in submission during this transition process and to which I had to justify 
successive changes in the procedures. 
 
Looking back at the internship, there are still a lot of aspects I need to improve if I aim to become a 
better CRC. I became more able to communicate naturally instead of getting nervous anytime, 
although I believe I could improve even more by using negotiation techniques and by expressing 
my point of view more clearly in every conversation. My time management skills were improved, 
mainly in HGO where time is a very scarce resource, and by having to conciliate the internship 
activities with the writing of this report. Although I feel that I leave the hospital in the end of the 
day with things left to be done frequently, and that indicates that time management still requires 
improvement.  
Overall, I made a lot of mistakes during my internship, and I must thank my colleagues in both 
hospitals for helping me overcome them. Facing mistakes can be demotivating sometimes, but my 
colleagues always told me the errors are a sign I am trying and everybody commits them. I learned 
a lot from my own errors: I became more oriented to solutions instead of self-punishment; and I 
could analyse my actions in order to identify the mistake not to repeat it. 
From the ground knowledge I gained, I now feel like I have the opportunity to grow on my own 
and to learn and accomplish more in my professional life.  
 
In general terms, I believe the initial goals were achieved. The main goal of understanding the role 
of a CRC was fully accomplished, and the secondary goals were also fulfilled although I should 
still work to improve them daily.  
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5. CONCLUSION 
This internship in Blueclinical was my first ever professional experience. I feel very grateful for 
having this opportunity of finishing and academic training already with a solid working experience. 
Clinical research coordination is a very wide activity that provides a good training basis to work as 
a CRC in the future, but also provided me with insights on other functions related to clinical trials. 
I believe that my theory background from the Master’s degree was a huge support to the activity I 
developed, as contents are very directed to daily practice approaches. The BSc degree was also 
helpful mostly for the soft skills I acquired. 
I also feel grateful for the opportunity of learning in the middle of such an innovative, young 
company. 
Actually, I am taking a professional internship for a year, also in Blueclinical, and I continue in 
HGO with the same functions as during the previous internship. 
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